focus -WSS

focus

author：leisure time 2025-10-02 17:21:56 - browse：48758

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Stem cell treatment guidelines are released by FDA

WSS

AstraZeneca chief proposes a novel edit to the drug pricing bill

Brain technologies pose threats that are all too real, experts warn

House transparency, PBM reform bill gains bipartisan support

Ethical issues complicate the benefits of medical crowdfunding

Black vets could get higher VA benefits if race not used in lung test

NIH nominee Bertagnolli will get October confirmation hearing

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

In Memoriam: Notable people who died in 2023

ALS advocates say criticism of new drugs misses bigger picture

State Dept. review finds Biden bears some blame for Afghanistan failures

Ethical issues complicate the benefits of medical crowdfunding

United colonoscopy coverage change 'may cost lives,' doctors say

BIO to announce reorganization, senior leaders expected to depart

Guidelines to prevent youth baseball injuries need more muscle

Brain MRIs reveal impact of 'toxic stress' on Black children

Cancer drug shortages should be causing more outrage

Warren pushes Witty on UnitedHealth's control over physicians

explore

AltruBio raises $225 million to develop ulcerative colitis drug

Primary care doctor shortage won't be solved by free med school tuition

BIO to announce reorganization, senior leaders expected to depart

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Why Novartis is changing the name of its research labs

The (many) problems with a new study criticizing cancer screening

hotspot

entertainment

focus

focus